GlobalData’s report assesses the drugs in the Protein Kinase C Theta Type pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
Relay Therapeutics has demonstrated resilience in the face of competition at the European Society for Medical Oncology (ESMO) meeting, particularly with its PI3K inhibitors for advanced breast cancer.
Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin.